AIM
LCTX icon

Athena Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Athena Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,556
Closed -$9K – 137
2022
Q3 		$9K Hold
35,556
– – 0.01% 128
2022
Q2 		$18K Hold
35,556
– – 0.01% 129
2022
Q1 		$70K Buy
+35,556
New +$55.2K 0.05% 119

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Athena Investment Management's LCTX Position: Q4 2022 in Review

Athena Investment Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2022, closing a stake of 35,556 shares — an estimated $9K sold.

Athena Investment Management first reported a position in LCTX in Q1 2022 and held it in 3 quarters. The position peaked at $70K in Q1 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • Athena Investment Management reported no remaining Lineage Cell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Athena Investment Management sold 35,556 Lineage Cell Therapeutics shares in Q4 2022, an estimated $9K.
  • Athena Investment Management first reported a position in Lineage Cell Therapeutics in Q1 2022 and held it in 3 quarters.
  • Athena Investment Management's Lineage Cell Therapeutics position peaked at $70K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Athena Investment Management's 13F filing for Q4 2022, filed 24 Feb 2023.